tbuckley/cabot-search huggingface dataset:
Abstract 454: Modeling <i>FLNC</i> Mutations Causing Cardiomyopathy
Authors: Joyce C Ohiri
Journal: Circulation Research (2020)

Genetic mutations lead to cardiomyopathy, a condition linked to heart failure and arrhythmias.Mutations in the FLNC gene have recently been reported in multiple forms of cardiomyopathyincluding dilated, hypertrophic and restrictive forms. The FLNC gene encodes filamin C, anactin-binding protein highly expressed in the heart and skeletal muscle. Filamin C is comprisedof three domains: an actin-binding domain at the N-terminus, a rod domain consisting of 24 Igrepeats in the mid region, and a dimerization domain at the C-terminus. Missense mutations in FLNC have also been described in myofibrillar myopathy, a disorder in skeletal musclecharacterized by intracellular aggregates within muscle. Where examined, FLNC mutant heartsdo not have evident protein aggregation leading to the hypothesis that FLNC mutations havedifferent modes of action in skeletal and cardiac muscle. We identified a FLNC Val2715fs87Xmutation in a 55 yo M with cardiac fibrosis and a history of arrhythmias. We found a second FLNC mutation, Glu2458SerfsX71, which was found in a family with sudden death andhypertrophic cardiomyopathy. A third FLNC mutation, Arg650X, was found in a 41 yo F withhistory of postpartum cardiomyopathy; this patient also harbors a second FLNC variant ofuncertain significance, intron 5, c.970-4A&gt;G (Intronic), which is predicted to affect splicing onher other FLNC allele. Notably, this patient was diagnosed with a muscle disorder in early life.Finally, a fourth FLNC variant, Phe106Leu, found in two brothers with skeletal and cardiacmyopathy was also studied. To examine the mechanisms by which FLNC mutations causecardiomyopathy, we generated patient-derived induced pluripotent stem cells (iPSCs) anddifferentiated these cell lines into cardiomyocytes. Cardiomyocyte function was analyzed usingautomated field potential measurements with the Nanion CardioExcyte. We identified a slowerrate of repolarization with FLNC truncations compared to control. These data demonstrate thepathogenic findings associated with FLNC mutations and provide mechanistic insight intocardiomyopathy and arrhythmias resulting from these mutations.
Treating Acute Leukemia during the COVID-19 Pandemic: A Multicenter Latin American Registry
Authors: Roberta Demichelis, Martha Alvarado, Jule F Vasquez, Nancy Delgado, Cynthia Gómez, Karla Adriana Espinosa, Ana Cooke, Andrea Milan, Andres Gomez-De Leon, Lee-Tsai Yu Ling, Daniel Estuardo Rosales, Alvaro Cabrero Garcia, Lauro Fabian Amador, Carmina Alejandra Córdova-Ramírez, Iván Murrieta-Álvarez, Juan Carlos Solís-Poblano, Elia Ixel Apodaca, Juan Rangel-Patiño, Jose Luis Álvarez, Luara Arana, Jose Antonio De la Peña-Celaya, María Eugenia Espitia, Eleazar Hernandez, Juan Manuel Perez, Rosa González-Rivera, María Fernanda García-Leyva, Estefania Peña, Monica Tejeda Romero, Carolina Balderas-Delgado, Jorge Cruz Rico, Guillermo Ruiz Arguelles, David Gomez-Almaguer
Journal: Blood (2020)
FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma
Authors: Sandra J. Casak, Martha Donoghue, Lola Fashoyin-Aje, Xiaoping Jiang, Lisa Rodriguez, Yuan-Li Shen, Yuan Xu, Xiling Jiang, Jiang Liu, Hong Zhao, William F. Pierce, Shubhangi Mehta, Kirsten B. Goldberg, Marc R. Theoret, Paul G. Kluetz, Richard Pazdur, Steven J. Lemery
Journal: Clinical Cancer Research (2020)

On May 29, 2020, the FDA approved atezolizumab for use in combination with bevacizumab, for the treatment of adult patients with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC) with no prior systemic treatment. The approval was based on data from Study IMbrave150, which randomly allocated (2:1) patients to receive either atezolizumab plus bevacizumab (atezolizumab-bevacizumab) or sorafenib. Overall survival (OS) and independently assessed progression-free survival (PFS) in the intent-to-treat population were the primary endpoints. At the time of the primary analysis, the estimated median OS could not be estimated in the atezolizumab-bevacizumab arm and was 13.2 months in the sorafenib arm [HR, 0.58; 95% confidence interval (CI), 0.42-0.79]. The estimated median PFS was 6.8 months (95% CI, 5.8-8.3) and 4.3 months (95% CI, 4.0-5.6) in the atezolizumab-bevacizumab and sorafenib arms, respectively. Adverse reactions occurring in >20% of patients receiving atezolizumab-bevacizumab were hypertension, fatigue/asthenia, and proteinuria. Adverse reactions occurring in >20% of patients receiving sorafenib were palmar-plantar erythrodysesthesia, diarrhea, hypertension, and decreased appetite. Hemorrhage was reported more frequently in patients receiving atezolizumab-bevacizumab (25%) than in patients receiving sorafenib (17%). An evaluation for the presence of varices is recommended within 6 months of initiation of atezolizumab-bevacizumab in patients with HCC. Approval of atezolizumab-bevacizumab is likely to change the treatment paradigm for HCC, given that treatment with atezolizumab-bevacizumab resulted in improved OS and PFS compared with sorafenib, an accepted standard of care for first-line treatment of patients with unresectable HCC.See related commentary by Castet et al., p. 1827.
Abstract 102: Sympathetic Innervation Negatively Regulates Postnatal Cardiomyocyte Proliferation Through Circadian Genes
Authors: Emmanouil Tampakakis, Sean Murphy, Harshi Gangrade, William Kowalski, Yosuke Mukoyama, Chulan Kwon
Journal: Circulation Research (2020)

Sympathetic neurons (SNs) regulate heart rate, conduction velocity, contractility and relaxation of the myocardium. Disruption of SNs in adult cardiac disease, leads to arrhythmias, myocardial dysfunction and sudden cardiac death. However, the role of SNs during cardiac development and whether disruption of cardiac SNs at embryonic stages is associated with disease progression in adult life is unknown. Moreover, controversy exists regarding the effect of SNs on neonatal myocardial regeneration after injury. As the heart is innervated by SNs from mid-gestation and the innervation continues through the neonatal stage, we generated genetically modified mice with profoundly reduced cardiac-specific sympathetic innervation starting at embryonic stages. Inhibition of sympathetic innervation resulted in larger heart size with increased number of myocytes that were smaller and more mononuclear. Analysis also confirmed increased cardiomyocyte proliferation. Interestingly, transcriptomic analysis of P7 and P14 hearts verified dysregulated cell cycle, calcium homeostasis and circadian genes. Remarkably, this led to persistently increased heart size and reduced function at adult stages. To investigate the mechanism whereby SNs, affect cardiomyocyte proliferation, we first co-cultured human stem cell-derived or mouse cardiomyocytes with ganglionic SNs and confirmed similar gene expression patterns. Moreover, alpha1 and beta2-specific adrenergic receptor agonists and norepinephrine, reduced cell cycle genes and myocyte proliferation and upregulated circadian genes such as Period1 and Period2. As circadian genes have been linked with regulation of cell cycle and apoptosis, we analyzed neonatal hearts from Period1/Period2 DKO mice and curiously discovered increased heart size, cardiomyocyte proliferation and cell cycle genes, and suppression of the Wee1 kinase an inhibitor of cell mitosis. More importantly, norepinephrine did not alter cardiomyocyte proliferation and cell cycle genes in Period1/Period2 DKO myocytes. To our knowledge this is the first study to provide direct evidence of the effect of SNs in the regulation of circadian genes in the heart and their role on neonatal cardiomyocyte proliferation.
Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study
Authors: James L. Januzzi, Javed Butler, Naveed Sattar, Jialin Xu, Wayne Shaw, Norman Rosenthal, Michael Pfeifer, Kenneth W. Mahaffey, Bruce Neal, Michael K. Hansen
Journal: Diabetes Care (2020)

OBJECTIVE To analyze the association between concentrations of plasma insulin-like growth factor binding protein 7 (IGFBP7) with renal and cardiac outcomes among participants with type 2 diabetes and high cardiovascular risk. RESEARCH DESIGN AND METHODS Associations between IGFBP7 levels and clinical outcomes were assessed among participants in the Canagliflozin Cardiovascular Assessment Study (CANVAS) with type 2 diabetes and high cardiovascular risk. RESULTS Among CANVAS participants, 3,577 and 2,898 had IGFBP7 measured at baseline and 1 year, respectively. Per log-unit higher concentration, baseline IGFBP7 was significantly associated with the composite renal end point of sustained 40% reduction in estimated glomerular filtration rate, need for renal replacement therapy, or renal death (hazard ratio [HR] 3.51; P &amp;lt; 0.001) and the composite renal end point plus cardiovascular death (HR 4.90; P &amp;lt; 0.001). Other outcomes, including development or progression of albuminuria, were also predicted by baseline IGFBP7. Most outcomes were improved by canagliflozin regardless of baseline IGFBP7; however, those with baseline concentrations ≥96.5 ng/mL appeared to benefit more from canagliflozin relative to the first progression of albuminuria compared with those with lower baseline IGFBP7 (HR 0.64 vs. 0.95; Pinteraction = 0.003). Canagliflozin did not lower IGFBP7 concentrations by 1 year; however, at 1 year, higher IGFBP7 concentrations more strongly predicted the composite renal end point (HR 15.7; P &amp;lt; 0.001). Patients with rising IGFBP7 between baseline and 1 year had the highest number of composite renal events. CONCLUSIONS Plasma IGFBP7 concentrations predicted renal and cardiac events among participants with type 2 diabetes and high cardiovascular risk. More data are needed regarding circulating IGFBP7 and progression of diabetic kidney disease and its complications.
Carbon Nanotubes: Construction of Aptamer‐siRNA Chimera/PEI/5‐FU/Carbon Nanotube/Collagen Membranes for the Treatment of Peritoneal Dissemination of Drug‐Resistant Gastric Cancer (Adv. Healthcare Mater. 21/2020)
Authors: Wen Chen, Sainan Yang, Xia Wei, Zailin Yang, Dongxu Liu, Xin Pu, Silian He, Yong Zhang
Journal: Advanced Healthcare Materials (2020)

In article number 2001153 by Yong Zhang and co-workers, aptamer-siRNA Chimera/PEI/5-FU/carbon nanotube (CNT)/collagen membranes are constructed to treat peritoneal dissemination of drug-resistant gastric cancer. Chimeras can specifically bind to gastric cancer cells, then 5-FU and chimeras are released. Chimeras are cut into siRNA by Dicer, which mediates targeted mRNA degradation.
Factors Affecting Transfusion Utilization in Acute Myeloid Leukemia (AML) Patients Undergoing Initial Therapy
Authors: Sangmin Lee, Priscilla Parra, Idongessit Udoyen, Kartikey Grover, Kathleen Kane, Pinkal Desai, Michael Samuel, Ellen K Ritchie, Gail J. Roboz, Melissa M. Cushing
Journal: Blood (2017)
Single 225μg/Kg Dose Treatment with Eptacog Beta (Factor VIIa, Recombinant) Results in Rapid Hemostasis in Joint Bleeds for Persons with Hemophilia Α or Β with Inhibitors: A PERSEPT1 Subset Analysis
Authors: Janna M. Journeycake, Cedric Hermans, Jonathan M. Ducore, Miguel A. Escobar, Guy Young, Michael Wang, Doris Quon, W Allan Alexander, Ian S Mitchell, Ahmad Al-Sabbagh, Daniel Bonzo
Journal: Blood (2020)
Excellent Outcomes in Patients with Primary and Secondary Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using a Rituximab, Busulfan, Melphalan, Thiotepa Conditioning Regimen
Authors: Shona Philip, Adrienne Fulford, Selay Lam, Chai Wye Phua, Joy Mangel, Kang Howson-Jan, Brandon Dorland, Karen Atkinson, Anargyros Xenocostas, Uday Deotare
Journal: Blood (2020)
SARS-CoV-2 in patients with chronic liver disease
Authors: Jordan Hindson
Journal: Nature Reviews Gastroenterology & Hepatology (2020)

S U r g e rY Antibiotics versus appendectomy for appendicitisTo assess the efficacy of antibiotic therapy compared with appendectomy for the treatment of appendicitis, a noninferiority trial in 1,552 adults with appendicitis or an appendicolith was conducted at 25 centres in the USA.Patients were randomized to receive either a 10-day course of antibiotics or to undergo surgery.Antibiotics were noninferior to appendectomy, based on the primary outcome of 30-day European Quality of Life-5 Dimensions questionnaire scores (mean difference, 0.01 points; 95% CI -0.001 to 0.03).Of the antibiotics group, 41% of those with an appendicolith and 25% of those without had undergone an appendectomy by 90 days after randomization.Complications were more common in the antibiotics group than in the appendectomy group.
Reply to Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et al’s Letter to the Editor re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti–PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269–76. Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation
Authors: Nick van Dijk, Alfonso Gómez de Liaño Lista, Bernadett Szabados, Thomas Powles, Michiel S. van der Heijden
Journal: European Urology (2020)
FRI0212 Correlation between histopathological findings, sero-immunological profile and markers of disease activity in sicca syndrome
Authors: M Benucci, A Mannoni, F Li Gobbi, U Serni
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> We evaluated sero-immunological parameters and markers of disease activity in ninety-two patients all female who underwent lip biopsy for histological assessment of sicca syndrome, according new preliminary criteria proposed for classification of Sjogren Syndrome (S. S). <h3>Objectives</h3> The aim of our study was to compare the histopathological score index according to Chisolm and Mason classification with twenty-two parameters of disease activity. <h3>Methods</h3> We have classified thirty-seven patients (group A) with focus score I-II with probable S. S (positivity of 3/6 item) and fifty-five patients (group B) with focus score III-IV with defined S. S (positivity of 4/6 item). The mean age of two group was: group A 60 ± 11 years, group B 64 ± 9.8 years. The statistical comparison between the two group was performed with T-Student for 20 parameters and chi-square method for ANA and SSA/SSB positivity. <h3>Results</h3> The comparison between the two groups show statistically significant differences for sero-immunological parameters such as gamma globulin (p &lt; 0.01), SSA/SSB (p &lt; 0.001). Moreover the group B shows higher levels of ESR (p &lt; 0.005), fibrinogen (p &lt; 0.02) and alpha1-antitrypsin (p &lt; 0.005). <h3>Conclusion</h3> This data show the important role of lip biopsy in the diagnosis of S:S and suggest the possible correlation between high histopathologic focus score and immunological markers of disease activity. <h3>References</h3> Vitali C, <i>et al</i>. Arthritis Rheum. 1992;36:340–8 Chisolm D, Mason D. J Clin Pathol. 1970;23: 690
Palmitoylethanolamide-Mediated Inhibition of Nogo-a Signaling Attenuates Pain in Sickle Mice
Authors: Donovan A Argueta, Hanan Chweih, Bryant Avalos, Huy Tran, Aithanh Nguyen, Anupam Aich, Nicholas V DiPatrizio, Kalpna Gupta
Journal: Blood (2020)
Efficacy of Daratumumab Based Regimens Compared to Standard of Care for Transplant Ineligible Newly Diagnosed Multiple Myeloma in Phase III Clinical Trials: A Meta-Analysis
Authors: Zahoor Ahmed, Karun Neupane, Rabia Ashraf, Amna Khan, Moazzam Shahzad, Muhammad Salman Faisal, Sana Irfan Khan, Abdul Rafae, Arshia Akbar, Ahsan Wahab, Hamid Ehsan, Faiz Anwer
Journal: Blood (2020)
Rap-536 Induces Reticulocyte Maturation in Wild-Type Mice, Increases Survival of Beta-Thalassemic Reticulocytes, and Increases Red Blood Cells in a Mouse Model of Alpha-Thalassemia
Authors: Melih Acar, Madhulika Jupelli, Roberto A. Abbiati, Harish N. Ramanathan, Cristina C. Santini, Alexander Ratushny, Diana R. Dunshee, Daniel Lopes de Menezes, Kyle MacBeth, Rajasekhar N.V.S. Suragani, Remco Loos, Martin Schwickart
Journal: Blood (2020)
Therapy-Related AML (t-AML), a Heterogeneous Disease: Multicenter Analysis on Biological and Clinical Differences between Cases Following Breast Cancer and Lymphoma Treatment
Authors: Giambattista Bertani, Fabio Guolo, Valentina Mancini, Rosa Greco, Paola Minetto, Monica Passannante, Roberto Massimo Lemoli, Roberto Cairoli
Journal: Blood (2020)
Abstract 15846: Ablation of Atrial Fibrillation Improves Left Ventricular Diastolic Function and Prevents HFpEF-Related Hospitalization in Super-Elderly Patients
Authors: Naoko Ikeda, Tomoko S Kato, Hiroto Fukuoka, Kohei Wakabayashi, Kaoru Tanno
Journal: Circulation (2019)

Introduction: Atrial fibrillation (AF) is the most common cardiac arrhythmia and its prevalence increases with age. Patients with AF carry a risk for the development of heart failure (HF). Especial...
MPL Overexpression Induces a High Level of Mutant-Calr/MPL Complex: A Novel Mechanism of Ruxolitinib Resistance in Myeloproliferative Neoplasms with Calr Mutations
Authors: Shunichiro Yasuda, Satoru Aoyama, Ryoto Yoshimoto, Daisuke Watanabe, Hiroki Akiyama, Kouhei Yamamoto, Takeo Fujiwara, Emiko Sakaida, Yoko Edahiro, Misa Imai, Marito Araki, Norio Komatsu, Norihiko Kawamata
Journal: Blood (2020)
Advancing OB/GYN Knowledge, Competence, and Performance Related to Abnormal Uterine Bleeding and Intravenous Iron Supplementation for Effective Management of Iron Deficiency Anemia: Outcomes Analysis from a 2019 Educational Initiative
Authors: Bryan C. Taylor, Lee P. Shulman, Malcolm G. Munro, Stephanie Martin, Anita L. Nelson, Patricia A. Locantore-Ford
Journal: Blood (2020)
Development of a Computable Phenotype for Hospital-Acquired Venous Thrombosis: The Medical Inpatient Thrombosis and Hemostasis (MITH) Study
Authors: Ryan M Thomas, Insu Koh, Katherine Wilkinson, Nicholas Roetker, Nicholas L Smith, Allen B Repp, Chris E. Holmes, Timothy B Plante, Mary Cushman, Neil A. Zakai
Journal: Blood (2020)
A Mouse Homolog of Mutant Wasp Responsible for X-Linked Neutropenia Causes Reduced Myeloid Progenitor Activity but Rather Increased Neutrophil Compartment in Bone Marrow
Authors: Masahiro Ikeda, Muneyoshi Futami, Bidisha Chanda, Masayuki Kobayashi, Kiyoko Izawa, Arinobu Tojo
Journal: Blood (2020)
Antibiotic Treatment Regimes as a Driver of the Global Population Dynamics of a Major Gonorrhea Lineage
Authors: Magnus N Osnes, Lucy van Dorp, Ola B Brynildsrud, Kristian Alfsnes, Thamarai Schneiders, Kate E Templeton, Koji Yahara, Francois Balloux, Dominique A Caugant, Vegard Eldholm
Journal: Molecular Biology and Evolution (2020)

The Neisseria gonorrhoeae multilocus sequence type (ST) 1901 is among the lineages most commonly associated with treatment failure. Here, we analyze a global collection of ST-1901 genomes to shed light on the emergence and spread of alleles associated with reduced susceptibility to extended-spectrum cephalosporins (ESCs). The genetic diversity of ST-1901 falls into a minor and a major clade, both of which were inferred to have originated in East Asia. The dispersal of the major clade from Asia happened in two separate waves expanding from ∼1987 and 1996, respectively. Both waves first reached North America, and from there spread to Europe and Oceania, with multiple secondary reintroductions to Asia. The ancestor of the second wave acquired the penA 34.001 allele, which significantly reduces susceptibility to ESCs. Our results suggest that the acquisition of this allele granted the second wave a fitness advantage at a time when ESCs became the key drug class used to treat gonorrhea. Following its establishment globally, the lineage has served as a reservoir for the repeated emergence of clones fully resistant to the ESC ceftriaxone, an essential drug for effective treatment of gonorrhea. We infer that the effective population sizes of both clades went into decline as treatment schemes shifted from fluoroquinolones via ESC monotherapy to dual therapy with ceftriaxone and azithromycin in Europe and the United States. Despite the inferred recent population size decline, the short evolutionary path from the penA 34.001 allele to alleles providing full ceftriaxone resistance is a cause of concern.
Aggression as a Mediating Behavior in the Association Between Video Game Use and Body Mass Index—Reply
Authors: William Goodman, Rebecca J. Beeken
Journal: JAMA Pediatrics (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Italian Observational Study on Real-Life Use of Venetoclax in Acute Myeloid Leukemia (AVALON study): Results of Interim Analysis on Relapsed/Refractory Patients
Authors: Elisabetta Todisco, Nicola Fracchiolla, Cristina Papayannidis, Maria Paola Martelli, Giuliana Rizzuto, Alessandro Cignetti, Nicola Di Renzo, Patrizia Zappasodi, Michele Gottardi, Ernesta Audisio, Monia Lunghi, Federica Gigli, Corrado Tarella, Chiara Zingaretti, Elisabetta Petracci, Roberta Volpi, Delia Cangini, Maria Benedetta Giannini, Mariarita Sciumè, Giuseppe Rossi, Avalon Group, Giovanni Martinelli, Claudio Cerchione
Journal: Blood (2020)
Trials in Progress: A Phase I Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants with Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High-Risk Myelodysplastic Syndrome
Authors: Lina Benajiba, Hetty E. Carraway, Nada Hamad, Eytan M. Stein, Costas K. Yannakou, Amy Burroughs, Scott Harris, Hayley Lane, Dorothy D. Nguyen, Monic Stuart, Jesse Vargas, Alexandre Puissant, Kimberly Stegmaier, Courtney D. DiNardo
Journal: Blood (2020)
Complex Karyotype Subtypes at Chronic Lymphocytic Leukemia Diagnosis Refine the Risk of Developing a Richter Syndrome. the Richter Syndrome Scoring System
Authors: Andrea Visentin, Gian Matteo Rigolin, Francesca Romana Mauro, Annalisa Martines, Federica Frezzato, Silvia Imbergamo, Stefano Pravato, Leila Romano Gargarella, Maria Antonella Bardi, Mauro Nanni, Francesco Piazza, Monica Facco, Robin Foà, Gianpietro Semenzato, Laura Bonaldi, Antonio Cuneo, Livio Trentin
Journal: Blood (2020)
Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer
Authors: Nina G. Steele, Eileen S. Carpenter, Samantha B. Kemp, Veerin R. Sirihorachai, Stephanie The, Lawrence Delrosario, Jenny Lazarus, El-ad David Amir, Valerie Gunchick, Carlos Espinoza, Samantha Bell, Lindsey Harris, Fatima Lima, Valerie Irizarry-Negron, Daniel Paglia, Justin Macchia, Angel Ka Yan Chu, Heather Schofield, Erik-Jan Wamsteker, Richard Kwon, Allison Schulman, Anoop Prabhu, Ryan Law, Arjun Sondhi, Jessica Yu, Arpan Patel, Katelyn Donahue, Hari Nathan, Clifford Cho, Michelle A. Anderson, Vaibhav Sahai, Costas A. Lyssiotis, Weiping Zou, Benjamin L. Allen, Arvind Rao, Howard C. Crawford, Filip Bednar, Timothy L. Frankel, Marina Pasca di Magliano
Journal: Nature Cancer (2020)